MX2024008983A - Polipeptidos quimericos - Google Patents

Polipeptidos quimericos

Info

Publication number
MX2024008983A
MX2024008983A MX2024008983A MX2024008983A MX2024008983A MX 2024008983 A MX2024008983 A MX 2024008983A MX 2024008983 A MX2024008983 A MX 2024008983A MX 2024008983 A MX2024008983 A MX 2024008983A MX 2024008983 A MX2024008983 A MX 2024008983A
Authority
MX
Mexico
Prior art keywords
amino acid
polypeptide
gingipain
lys
arg
Prior art date
Application number
MX2024008983A
Other languages
English (en)
Spanish (es)
Inventor
Eric Charles Reynolds
Nada Slakeski
Neil O''brien-Simpson
Original Assignee
Denteric Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2022900101A external-priority patent/AU2022900101A0/en
Application filed by Denteric Pty Ltd filed Critical Denteric Pty Ltd
Publication of MX2024008983A publication Critical patent/MX2024008983A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0216—Bacteriodetes, e.g. Bacteroides, Ornithobacter, Porphyromonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/22037—Gingipain R (3.4.22.37)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/22047—Gingipain K (3.4.22.47)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2024008983A 2022-01-20 2024-07-19 Polipeptidos quimericos MX2024008983A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2022900101A AU2022900101A0 (en) 2022-01-20 Chimeric polypeptides
PCT/AU2023/050028 WO2023137519A1 (en) 2022-01-20 2023-01-20 Chimeric polypeptides

Publications (1)

Publication Number Publication Date
MX2024008983A true MX2024008983A (es) 2024-11-08

Family

ID=87347480

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024008983A MX2024008983A (es) 2022-01-20 2024-07-19 Polipeptidos quimericos

Country Status (9)

Country Link
EP (1) EP4466011A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025503079A (cg-RX-API-DMAC7.html)
KR (1) KR20240149404A (cg-RX-API-DMAC7.html)
CN (1) CN118891059A (cg-RX-API-DMAC7.html)
AU (1) AU2023209795A1 (cg-RX-API-DMAC7.html)
CA (1) CA3248847A1 (cg-RX-API-DMAC7.html)
IL (1) IL314282A (cg-RX-API-DMAC7.html)
MX (1) MX2024008983A (cg-RX-API-DMAC7.html)
WO (1) WO2023137519A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121604975A (zh) * 2023-07-26 2026-03-03 丹特瑞克有限公司 Rna疫苗
WO2025019900A1 (en) * 2023-07-26 2025-01-30 Denteric Pty Ltd Chimeric protein vaccine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ485999A0 (en) * 1999-12-24 2000-02-03 Csl Limited P. gingivalis antigenic composition
EP2328914B1 (en) * 2008-08-29 2017-05-10 Oral Health Australia Pty Ltd Prevention, treatment and diagnosis of p.gingivalis infection
WO2014183168A1 (en) * 2013-05-14 2014-11-20 Oral Health Australia Pty Ltd Inhibitory propeptides

Also Published As

Publication number Publication date
JP2025503079A (ja) 2025-01-30
CN118891059A (zh) 2024-11-01
EP4466011A4 (en) 2026-04-08
KR20240149404A (ko) 2024-10-14
WO2023137519A1 (en) 2023-07-27
EP4466011A1 (en) 2024-11-27
AU2023209795A1 (en) 2024-08-01
CA3248847A1 (en) 2023-07-27
IL314282A (en) 2024-09-01

Similar Documents

Publication Publication Date Title
AR108442A1 (es) Proteínas de fusión gdf15 y usos de estas
MX2024015050A (es) L-asparaginasa modificada
PE20120021A1 (es) Mutantes fgf21
AR123978A1 (es) Variantes de la interleucina-18 y métodos de uso
ES2534744T3 (es) Plasmina modificada de forma recombinante
MX2009004147A (es) Vacunas de peptido para canceres que expresan polipeptidos mphosph1 o depdc1.
CO2021014778A2 (es) Subunidad s1 modificada de la proteína de espícula de coronavirus
MX339277B (es) Agente inductor de inmunidad.
AR076977A1 (es) Proteinas precursoras repetitivas autoensambladas
NZ628987A (en) Extended recombinant polypeptides and compositions comprising same
CL2011003121A1 (es) Proteína de fusión que comprende una secuencia de hormona de crecimiento (gh), ligada a un polipéptido recombinante extendido (xten) que comprende al menos 200 aminoácidos, carece de epítopes de células t y los residuos g, a, s, t, e y p suman más del 90%; ácido nucleico, vector y célula; método de producción; composición farmacéutica y uso.
AR069996A1 (es) Plantas con caracteristicas aumentadas relacionadas con el rendimiento y un metodo para desarrollar las mismas
AR071874A1 (es) Proteinas de dominio de armazon basadas en fibronectina multivalentes
PE20120358A1 (es) Mutantes fgf21 y usos de los mismos
EA201592306A1 (ru) Вакцины против вируса гриппа и их применения
CO2022014871A2 (es) Polipéptidos variantes proteolíticamente estables de u1-agatoxina-ta1b para el control de plagas
BRPI0606612A2 (pt) expressão recombinante de proteìnas em uma forma de duas cadeias ligadas por dissulfeto
PE20160507A1 (es) Diferenciacion de celulas madre mesenquimales
CO6220834A2 (es) Composiciones y metodos de aplicacion topica y suministro transdermico de toxinas botulinum estabilizadas con fragmentos de polipeptido derivado de hiv-tat
AR114960A1 (es) Proteína tolerante a herbicida, gen codificante y uso de la misma
AR123187A1 (es) Vacuna de múltiples epítopos para el tratamiento de la enfermedad de alzheimer
BR112018003594A2 (pt) cadeia pesada de imunoglobulina recombinante, anticorpos, método de produção de conjugado e conjugados
AR116876A1 (es) Vacuna de ibv 4/91 con proteína espicular heteróloga
PE20220500A1 (es) POLIPEPTIDO DE FUSION QUE COMPRENDE LA REGION Fc DE INMUNOGLOBULINA Y GDF15
AR125379A1 (es) Un fab anti-tslp con estabilidad mejorada